相关临床试验
194
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1902
进行中（未招募）
1
0.5%
已完成
65
33.5%
Enrolling By Invitation
2
1.0%
尚未招募
5
2.6%
招募中
11
5.7%
暂停
4
2.1%
终止
12
6.2%
Unknown
85
43.8%
撤回
9
4.6%
暂无批准数据
- Amorphical has enrolled the first patient in a Phase 2 clinical trial evaluating its investigational nano-amorphous mineral-based therapy for Stage IV pancreatic cancer patients. - The study aims to investigate whether the therapy can extend patient survival by measuring progression-free survival, overall survival, response rate, and quality of life improvements. - The novel technology is designed to selectively buffer the tumor microenvironment by normalizing tumor acidity, potentially restoring immune activity and enhancing responses to standard treatments. - With Stage IV pancreatic cancer having only a 3% five-year survival rate, the trial addresses a critical unmet medical need with data expected in Q3 2026.
- Minovia Therapeutics' MNV-201 demonstrated high safety profile with no drug-related adverse events in seven patients with low-risk myelodysplastic syndrome during Phase 1b trial. - One patient achieved transfusion independence with sustained hemoglobin improvements lasting over 10 months, along with enhanced mitochondrial function biomarkers. - Preclinical studies at Memorial Sloan Kettering Cancer Center showed the mitochondrial augmentation technology delayed leukemic progression and improved survival in MDS animal models. - The company will present these findings at the 67th ASH Annual Meeting, highlighting the potential of mitochondrial augmentation to prevent disease progression to acute myeloid leukemia.
- Merck KGaA has become a strategic partner in Peregrine Ventures' Incentive Incubator, gaining early access to startups in bioconvergence, pharma, and biotechnology fields. - The collaboration will focus on ventures with significant market potential aligned with Merck's three global divisions: Healthcare, Life Science, and Electronics, with priority given to bioconvergence ventures. - Through this partnership, eligible startups will receive support including investments, regulatory guidance, business development assistance, and potentially early-phase trial planning.
